Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.

González-Juarbe N, Shen H, Bergman MA, Orihuela CJ, Dube PH.

PLoS One. 2017 Feb 16;12(2):e0172314. doi: 10.1371/journal.pone.0172314. eCollection 2017.

2.

The route less taken: pulmonary models of enteric Gram-negative infection.

Fisher ML, Sun W, Curtiss R 3rd.

Pathog Dis. 2014 Mar;70(2):99-109. doi: 10.1111/2049-632X.12109. Epub 2013 Nov 21. Review.

3.

Roles of chaperone/usher pathways of Yersinia pestis in a murine model of plague and adhesion to host cells.

Hatkoff M, Runco LM, Pujol C, Jayatilaka I, Furie MB, Bliska JB, Thanassi DG.

Infect Immun. 2012 Oct;80(10):3490-500. doi: 10.1128/IAI.00434-12. Epub 2012 Jul 30.

4.

An encapsulated Yersinia pseudotuberculosis is a highly efficient vaccine against pneumonic plague.

Derbise A, Cerdà Marín A, Ave P, Blisnick T, Huerre M, Carniel E, Demeure CE.

PLoS Negl Trop Dis. 2012;6(2):e1528. doi: 10.1371/journal.pntd.0001528. Epub 2012 Feb 14.

5.

Pulmonary infection by Yersinia pestis rapidly establishes a permissive environment for microbial proliferation.

Price PA, Jin J, Goldman WE.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3083-8. doi: 10.1073/pnas.1112729109. Epub 2012 Feb 1.

6.

Developing live vaccines against plague.

Sun W, Roland KL, Curtiss R 3rd.

J Infect Dev Ctries. 2011 Sep 14;5(9):614-27. Review.

7.

Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion.

Embry A, Meng X, Cantwell A, Dube PH, Xiang Y.

Vaccine. 2011 Jul 26;29(33):5331-9. doi: 10.1016/j.vaccine.2011.05.088. Epub 2011 Jun 12.

8.

Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Ramasamy S, Liu CQ, Tran H, Gubala A, Gauci P, McAllister J, Vo T.

Br J Pharmacol. 2010 Oct;161(4):721-48. doi: 10.1111/j.1476-5381.2010.00939.x. Review.

9.

YopH inhibits early pro-inflammatory cytokine responses during plague pneumonia.

Cantwell AM, Bubeck SS, Dube PH.

BMC Immunol. 2010 Jun 16;11:29. doi: 10.1186/1471-2172-11-29.

10.

NMR-based design and evaluation of novel bidentate inhibitors of the protein tyrosine phosphatase YopH.

Leone M, Barile E, Vazquez J, Mei A, Guiney D, Dahl R, Pellecchia M.

Chem Biol Drug Des. 2010 Jul;76(1):10-6. doi: 10.1111/j.1747-0285.2010.00982.x. Epub 2010 Apr 28.

12.

A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.

Oyston PC, Mellado-Sanchez G, Pasetti MF, Nataro JP, Titball RW, Atkins HS.

Microb Pathog. 2010 May;48(5):191-5. doi: 10.1016/j.micpath.2010.01.005. Epub 2010 Jan 22.

13.

Tipping the balance by manipulating post-translational modifications.

Broberg CA, Orth K.

Curr Opin Microbiol. 2010 Feb;13(1):34-40. doi: 10.1016/j.mib.2009.12.004. Epub 2010 Jan 12. Review.

14.

The smpB-ssrA mutant of Yersinia pestis functions as a live attenuated vaccine to protect mice against pulmonary plague infection.

Okan NA, Mena P, Benach JL, Bliska JB, Karzai AW.

Infect Immun. 2010 Mar;78(3):1284-93. doi: 10.1128/IAI.00976-09. Epub 2010 Jan 11.

15.

The role of relA and spoT in Yersinia pestis KIM5 pathogenicity.

Sun W, Roland KL, Branger CG, Kuang X, Curtiss R 3rd.

PLoS One. 2009 Aug 24;4(8):e6720. doi: 10.1371/journal.pone.0006720.

16.

D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Szaba FM, Kummer LW, Wilhelm LB, Lin JS, Parent MA, Montminy-Paquette SW, Lien E, Johnson LL, Smiley ST.

Infect Immun. 2009 Oct;77(10):4295-304. doi: 10.1128/IAI.00273-09. Epub 2009 Jul 20.

17.

Gr1+ cells control growth of YopM-negative yersinia pestis during systemic plague.

Ye Z, Kerschen EJ, Cohen DA, Kaplan AM, van Rooijen N, Straley SC.

Infect Immun. 2009 Sep;77(9):3791-806. doi: 10.1128/IAI.00284-09. Epub 2009 Jul 6.

18.

Immune defense against pneumonic plague.

Smiley ST.

Immunol Rev. 2008 Oct;225:256-71. doi: 10.1111/j.1600-065X.2008.00674.x. Review.

19.

Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.

Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE.

Infect Immun. 2008 Aug;76(8):3808-16. doi: 10.1128/IAI.00034-08. Epub 2008 May 27.

20.

Current challenges in the development of vaccines for pneumonic plague.

Smiley ST.

Expert Rev Vaccines. 2008 Mar;7(2):209-21. doi: 10.1586/14760584.7.2.209. Review.

Supplemental Content

Support Center